{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:18:59Z","timestamp":1787505539962,"version":"build-2736575974"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T00:00:00Z","timestamp":1662940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"\n Background<\/jats:title>\n Several trials have considered the safety and clinical benefits of colchicine as a treatment option for secondary prevention in patients with coronary atherosclerotic heart disease (CAD), but its safety and clinical benefits remain controversial. The purpose of this study was to explore the clinical benefits of colchicine, focusing on certain subgroups of patients.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Randomized controlled trials (RCTs) of colchicine in subjects with acute or chronic CAD compared with controls were included to assess all-cause mortality, non-cardiovascular mortality, gastrointestinal adverse effects, diarrhea, MACE, cardiovascular mortality, MI, stroke, and revascularization. We analyzed the association of cardiovascular, mortality, and gastrointestinal risk with colchicine in all subjects. We also focused on the cardiovascular risk of colchicine in subgroups with different drug doses, different treatment durations, age, gender, and associated comorbidities.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n This meta-analysis included 15 clinical RCTs, including 13,539 subjects. Colchicine reduced the risk of MACE (RR: 0.65; 95% CI: 0.38\u20130.77, p for heterogeneity &lt; 0.01; I2 = 70%;\n p<\/jats:italic>\n &lt; 0.01), stroke (RR: 0.48; 95% CI: 0.30\u20130.76; p heterogeneity = 0.52; I2 = 0%;\n p<\/jats:italic>\n &lt; 0.01), MI by 40% (RR: 0.60; 95% CI: 0.43\u20130.83; p for heterogeneity = 0.01; I2 = 59%;\n p<\/jats:italic>\n &lt; 0.01) and risk of revascularization (RR: 0.68; 95% CI: 0.56\u20130.83; p for heterogeneity = 0.17; I2 = 40%;\n p<\/jats:italic>\n &lt; 0.01), but had no significant effect on risk of cardiovascular death and risk of all-cause mortality. In addition, colchicine increased the risk of gastrointestinal side effects and diarrhea. In a subgroup analysis, low-dose colchicine and treatment duration &gt; 1 month reduced the risk of MACE, MI, stroke, and revascularization. Also, the cardiovascular benefits of colchicine were observed in subjects up to 65 years of age. The results showed that hypertension and diabetes did not have a specific effect on colchicine and MACE risk.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Colchicine has a positive effect in reducing the incidence of MACE, MI, stroke, and revascularization, but can increase the risk of gastrointestinal and diarrhea events. Low-dose colchicine significantly reduces the risk of MACE more than high-dose colchicine, and the benefits of long-term treatment are higher than those of short-term treatment. Long-term low-dose colchicine treatment may significantly reduce the risk of cardiovascular events. Furthermore, colchicine significantly reduced the risk of cardiovascular events in patients up to 65 years of age, but it did not appear to reduce cardiovascular risk in patients over 65 years of age or in preoperative PCI patients.<\/jats:p>\n <\/jats:sec>\n \n Systematic review registration<\/jats:title>\n \n [\n https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n ], identifier [CDR42022332170].\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fcvm.2022.947959","type":"journal-article","created":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T11:54:22Z","timestamp":1662983662000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Colchicine and coronary heart disease risks: A meta-analysis of randomized controlled clinical trials"],"prefix":"10.3389","volume":"9","author":[{"given":"Zijun","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/euhj.2001.2956","article-title":"Inflammation, infection, and coronary heart disease.","volume":"23","author":"Wilhelmsen","year":"2002","journal-title":"Eur Heart J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1055\/s-0033-1349426","article-title":"[Chronic inflammation and atherosclerosis].","volume":"138","author":"von Hundelshausen","year":"2013","journal-title":"Dtsch Med Wochenschr."},{"key":"B3","doi-asserted-by":"publisher","first-page":"687","DOI":"10.5694\/mja14.00846","article-title":"Colchicine\u2013a short history of an ancient drug.","volume":"201","author":"Nerlekar","year":"2014","journal-title":"Med J Austr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semarthrit.2017.03.006","article-title":"Colchicine resistance and intolerance in familial mediterranean fever: definition, causes, and alternative treatments.","volume":"47","author":"Ozen","year":"2017","journal-title":"Semin Arthritis Rheum."},{"key":"B5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nature02393","article-title":"Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain.","volume":"428","author":"Ravelli","year":"2004","journal-title":"Nature."},{"key":"B6","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/0163-7258(91)90067-v","article-title":"Interactions of colchicine with tubulin.","volume":"51","author":"Hastie","year":"1991","journal-title":"Pharmacol Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease.","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction.","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/bcp.15041","article-title":"Efficacy and safety of colchicine in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.","volume":"88","author":"Byty\u00e7i","year":"2022","journal-title":"Br J Clin Pharmacol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s10067-022-06050-0","article-title":"Colchicine may become a new cornerstone therapy for coronary artery disease: a meta-analysis of randomized controlled trials.","volume":"41","author":"Chen","year":"2022","journal-title":"Clin Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1186\/s12872-021-02393-9","article-title":"Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial.","volume":"21","author":"Akrami","year":"2021","journal-title":"BMC Cardiovasc Disord."},{"key":"B13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease.","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease.","volume":"135","author":"Robinson","year":"2022","journal-title":"Am J Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.acvd.2016.10.004","article-title":"COLIN trial: value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response.","volume":"110","author":"Akodad","year":"2017","journal-title":"Arch Cardiovasc Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"e008717","DOI":"10.1161\/CIRCINTERVENTIONS.119.008717","article-title":"Effects of acute colchicine administration prior to percutaneous coronary intervention: COLCHICINE-PCI randomized trial.","volume":"13","author":"Shah","year":"2020","journal-title":"Circ Cardiovasc Interv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s11239-011-0637-y","article-title":"Effect of colchicine compared with placebo on high sensitivity C-reactive protein in patients with acute coronary syndrome or acute stroke: a pilot randomized controlled trial.","volume":"33","author":"Raju","year":"2012","journal-title":"J Thromb Thrombolysis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.amjcard.2015.02.036","article-title":"Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting.","volume":"115","author":"Giannopoulos","year":"2015","journal-title":"Am J Cardiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1161\/CIRCULATIONAHA.115.017611","article-title":"Anti-inflammatory treatment with colchicine in acute myocardial infarction: a pilot study.","volume":"132","author":"Deftereos","year":"2015","journal-title":"Circulation."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5935\/abc.20160082","article-title":"Colchicine to reduce atrial fibrillation in the postoperative period of myocardial revascularization.","volume":"107","author":"Zarpelon","year":"2016","journal-title":"Arq Bras Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"ehz745.0994","DOI":"10.1093\/eurheartj\/ehz745.0994","article-title":"P4611Colchicine before percutaneous coronary intervention in acute myocardial infarction.","volume":"40","author":"Talasaz","year":"2019","journal-title":"Eur Heart J."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial.","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ahj.2019.06.003","article-title":"The low dose colchicine after myocardial infarction (LoDoCo-MI) study: a pilot randomized placebo controlled trial of colchicine following acute myocardial infarction.","volume":"215","author":"Hennessy","year":"2019","journal-title":"Am Heart J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/0735-1097(92)90624-v","article-title":"Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty.","volume":"19","author":"O\u2019Keefe","year":"1992","journal-title":"J Am Coll Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","article-title":"Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients.","volume":"61","author":"Deftereos","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1161\/CIRCULATIONAHA.121.056177","article-title":"Effect of colchicine on myocardial injury in acute myocardial infarction.","volume":"144","author":"Mewton","year":"2021","journal-title":"Circulation."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e021198","DOI":"10.1161\/JAHA.121.021198","article-title":"Colchicine in patients with coronary artery disease: a systematic review and meta-analysis of randomized trials.","volume":"10","author":"Kofler","year":"2021","journal-title":"J Am Heart Assoc."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1093\/eurjpc\/zwab045","article-title":"Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12 869 patients.","volume":"28","author":"Andreis","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.amjcard.2020.10.043","article-title":"Meta-analysis evaluating the utility of colchicine in secondary prevention of coronary artery disease.","volume":"140","author":"Xia","year":"2021","journal-title":"Am J Cardiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jjcc.2020.11.010","article-title":"Drug repurposing? Cardiovascular effect of colchicine on patients with coronary artery disease: a systematic review and meta-analysis.","volume":"77","author":"Tien","year":"2021","journal-title":"J Cardiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: the dark side of an ancient drug.","volume":"48","author":"Finkelstein","year":"2010","journal-title":"Clin Toxicol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis.","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.carrev.2021.09.006","article-title":"COlchicine to prevent periprocedural myocardial injury in percutaneous coronary intervention (COPE-PCI): a descriptive cytokine pilot sub-study.","volume":"39","author":"Cole","year":"2022","journal-title":"Cardiovasc Revasc Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.jacc.2021.05.022","article-title":"The coronary artery risk development in young adults (CARDIA) study: JACC focus seminar.","volume":"78","author":"Lloyd-Jones","year":"2021","journal-title":"J Am Coll Cardiol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.947959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T11:54:25Z","timestamp":1662983665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.947959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,12]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2022.947959"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.947959","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,12]]},"article-number":"947959"}}